-
CNOOC's CBM Endeavor - Analyst Blog
Thursday, December 30, 2010 - 12:15pm | 543China National Offshore Oil Corporation (or CNOOC Group), the parent company of CNOOC Ltd. (CEO), is heading toward an agreement to acquire 50% interest in China United Coal Bed Methane Company Limited (“CUCMB”) for 1.2 billion yuan ($181.2 million). The move reflects the group's endeavor to...
-
Piper Jaffray Introduces 2012 Estimates On QGEN
Thursday, December 30, 2010 - 9:03am | 156Piper Jaffray said today that, consistent with its recovery thesis, it is modeling an increase in Qiagen NV's (NASDAQ: QGEN) constant currency growth from 8.6% in 2011 to 9.4% in 2012, “with the potential for upside, in our opinion, back to the company's long-term stated goal of ‘double digit...
-
A Peek Into The Market Before The Trading Starts
Thursday, December 30, 2010 - 8:46am | 519Pre-open movers US stock futures are lower this morning, ahead of employment and manufacturing data. Futures for the Dow Jones Industrial Average dropped 12 points to 11,520, while futures for the S&P 500 fell 1.60 points to 1,254. Futures for the Nasdaq 100 lost 1 point to 2,228. A Peek Into...
-
Compugen Signs $5 Million R&D Funding Agreement
Thursday, December 30, 2010 - 8:28am | 82Compugen Ltd. (NASDAQ: CGEN) announced today that it has entered into an agreement with Baize Investments Ltd. under which it will receive $5,000,000 in R&D funding. Under the terms of the funding agreement, which is in support of Compugen's recently announced Pipeline Program, Baize...
-
Theravance Evenly Poised - Analyst Blog
Wednesday, December 29, 2010 - 5:33pm | 710We are maintaining our Neutral recommendation on Theravance Inc. (THRX) with a target price of $27. Theravance founded in 1996 and headquartered in South San Francisco, California focuses on the discovery, development and commercialization of small molecule medicines. The company develops...
-
Theravance Evenly Poised - Analyst Blog
Wednesday, December 29, 2010 - 5:09pm | 710We are maintaining our Neutral recommendation on Theravance Inc. (THRX) with a target price of $27. Theravance founded in 1996 and headquartered in South San Francisco, California focuses on the discovery, development and commercialization of small molecule medicines. The company develops...
-
Cephalon Drops Jet Lag Indication - Analyst Blog
Wednesday, December 29, 2010 - 11:33am | 598Cephalon Inc. (CEPH) recently announced that it no longer intends to pursue for the approval of Nuvigil for the treatment of patients with excessive sleepiness associated with jet lag disorder resulting from eastbound travel. The company arrived at this decision following the receipt of a second...
-
BASi Partners With Pharmasset
Wednesday, December 29, 2010 - 11:27am | 61BASi (NASDAQ: BASI) has entered into a Preferred Provider Agreement (PPA) with Princeton, New Jersey-based Pharmasset Inc. (NASDAQ: VRUS). The agreement includes provisions to provide exclusive toxicology services as well as pharmaceutical analysis and bioanalytical services as needed.
-
Verdict on MNKD's Afrezza Deferred - Analyst Blog
Wednesday, December 29, 2010 - 11:03am | 541Recently, the US Food and Drug Administration (FDA) stated that it will not be able to arrive at a decision regarding MannKind Corporation's (MNKD) inhaled insulin candidate, Afrezza, by December 29, 2010 as announced previously. The US regulatory body stated that it will need approximately 4...
-
Cephalon Drops Jet Lag Indication - Analyst Blog
Wednesday, December 29, 2010 - 11:00am | 598Cephalon Inc. (CEPH) recently announced that it no longer intends to pursue for the approval of Nuvigil for the treatment of patients with excessive sleepiness associated with jet lag disorder resulting from eastbound travel. The company arrived at this decision following the receipt of a second...
-
Verdict on MNKD's Afrezza Deferred - Analyst Blog
Wednesday, December 29, 2010 - 10:30am | 541Recently, the US Food and Drug Administration (FDA) stated that it will not be able to arrive at a decision regarding MannKind Corporation's (MNKD) inhaled insulin candidate, Afrezza, by December 29, 2010 as announced previously. The US regulatory body stated that it will need approximately 4...
-
Mid-Day Market Losers (XOMA, DARA, BPAX, BASI)
Tuesday, December 28, 2010 - 1:12pm | 106XOMA Ltd (NASDAQ: XOMA) shares dipped 20.03% to $4.91 by 12:00 pm. XOMA's trailing-twelve-month ROE is -461.17%. DARA Biosciences Inc (NASDAQ: DARA) shares dropped 17.95% to $3.20. DARA's trailing-twelve-month ROE is -394.10%. Biosante Pharmaceuticals Inc (NASDAQ: BPAX) lost 17.50% to $1.65. BPAX...
-
CRL for Alimera's Eye drug - Analyst Blog
Tuesday, December 28, 2010 - 12:00pm | 480Recently, Alimera Sciences Inc. (ALIM) faced a huge blow when the US Food and Drug Administration (FDA) refused to approve its lead candidate Iluvien in the present form due to insufficiency of data and issued a complete response letter (CRL). Moreover, the US regulatory body, while issuing the...
-
CRL for Alimera's Eye drug - Analyst Blog
Tuesday, December 28, 2010 - 10:45am | 480Recently, Alimera Sciences Inc. (ALIM) faced a huge blow when the US Food and Drug Administration (FDA) refused to approve its lead candidate Iluvien in the present form due to insufficiency of data and issued a complete response letter (CRL). Moreover, the US regulatory body, while issuing the...
-
Options Brief: BioDelivery Sciences International (BDSI)
Tuesday, December 28, 2010 - 10:38am | 82Shares of BioDelivery Sciences International (NASDAQ: BDSI) are higher on the session by 1.75%, trading at $2.90. Overall put volume is now running at 29.27x the daily average, with 50% of all puts traded being purchases on the offer. 6,000 contracts have traded on the session so far. BioDelivery...